OncoMatch

OncoMatch/Clinical Trials/NCT06908928

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Is NCT06908928 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including bulumtatug fuvedotin and bulumtatug fuvedotin for triple negative breast cancer.

Phase 1RecruitingMabwell (Shanghai) Bioscience Co., Ltd.NCT06908928Data as of May 2026

Treatment: bulumtatug fuvedotin · bulumtatug fuvedotin — The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

Check if I qualify

Extracted eligibility criteria

Cancer type

Triple-Negative Breast Cancer

Breast Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 3 prior lines

Must have received: taxane

Patient has received prior treatment with a taxane

Must have received: antibody-drug conjugate

Patient has received prior treatment with ... an antibody-drug conjugate with a topoisomerase inhibitor payload

Cannot have received: antibody-drug conjugate (enfortumab vedotin, tisotumab vedotin)

Have received any prior treatment with enfortumab vedotin, tisotumab vedotin or other MMAE based or nectin-4 targeted antibody-drug conjugates

Lab requirements

Blood counts

Adequate hematologic function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Adequate hematologic and organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope · Duarte, California
  • UCSD Moores Cancer Center · La Jolla, California
  • Anschutz Medical Center · Aurora, Colorado
  • UChicago Medicine Comprehensive Cancer Center · Chicago, Illinois
  • Massachusetts General Hospital · Boston, Massachusetts

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify